Effect of vitamin D administration on sepsis score and C-reactive protein (CRP) levels in preterm infants with neonatal sepsis: a randomized controlled trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Neonatal sepsis remains a leading cause of mortality in preterm infants.

While Vitamin D possesses immunomodulatory properties, evidence for its adjuvant role in sepsis is limited.

Who Took Part

PubMed tags the participants as both men and women.

How the Study Was Run

The design is described as randomized and open-label.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

An open-label, randomized controlled trial was conducted in Indonesia (August-December 2025) involving preterm infants (28-36 weeks) with sepsis.

Outcomes included changes in the modified Töllner score, Sepsis Prediction Score (SPS), and serum CRP.

Analysis was performed using ANCOVA and UNIANOVA, with laboratory analysts blinded to group allocation to strengthen the internal validity.

What Was Measured

Topics PubMed links to this paper include C-Reactive Protein, Vitamin D, Neonatal Sepsis, Infant, Premature, Vitamins and Indonesia.

The authors tagged it with the keywords Adjuvant therapy and Preterm infants.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (BMC pediatrics), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.